Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients

Clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption.

By actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Recurrent Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Location contact

Michael B Gill

CONTACT

https://www.withpower.com/[email protected]

415-900-4227

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged ≥ 18 years old
Able to comprehend the investigational nature of the protocol and provide informed consent
Diagnosis of recurrent ovarian cancer

Exclusion criteria

No diagnosis of recurrent ovarian cancer confirmed
Inability to perform regular electronic reporting
Patient does not understand, sign, and return consent form

Treatment and study plan

Primary outcomes

Number of patients who decide to participate in a recurrent ovarian cancer clinical trial

Time frame: 3 months
Rate of patients who remain in recurrent ovarian cancer clinical research to trial completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

415-900-4227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Delving Into the Patterns of Patient Engagement and Trends in Participation Within Recurrent Ovarian Cancer Clinical Trials

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Oct 6, 2023
Registry last updated: Oct 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting